Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours

Inclusion Criteria:

* Age \>=18 years.
* Histological or cytological documentation of non hematologic, malignant solid tumour.
* Have failed at least one previous therapeutic regimen.
* Measurable disease according to RECIST 1.1.
* Life expectancy \>= 12 weeks
* ECOG Performance Status of 0 or 1
* Written, signed and dated informed consent
* Able and willing to meet all protocol-required treatments, investigations and visits.
* Have adequate organ function

Exclusion Criteria:

* Clinically significant non-malignant disease.
* Active CNS metastases.
* Subjects with uncontrolled diabetes.
* History of clinically significant adverse drug reaction to heparin or other anti-coagulant agents
* History of immune-mediated thrombocytopaenia or other platelet abnormalities or other hereditary or acquired coagulopathies.
* Concomitant use of aspirin (\> 150 mg/day), NSAIDs (except COX-2 selective inhibitors), vitamin K antagonists (other than low-dose prophylactic use), heparin within two weeks prior to randomisation, or other anti-platelet drugs.
* History of severe allergic, anaphylactic or other significant adverse reaction to radiographic contrast media
* Known seropositivity to the human immunodeficiency virus (HIV)
* Women who are pregnant or breast-feeding.
* Women of child-bearing potential and male subjects who are partners of women of childbearing potential who are unable or unwilling to practice a highly effective means of contraception.
* Active substance abuse
* Subjects who have received an investigational agent within 28 days prior to Cycle 1 Day 1.